Pharsight

Drug Patents Expiring in 2034

1. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(9 years from now)

US11648347 OTSUKA PHARM CO LTD Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-746) Jul 27, 2020
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

2. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10097388 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US9787511 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US9270503 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046 BRISTOL-MYERS Methods of treating pancreatic cancer
Jan, 2034

(9 years from now)

US9511046

(Pediatric)

BRISTOL-MYERS Methods of treating pancreatic cancer
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 06, 2023
M(M-14) Dec 06, 2022
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
New Indication(I-658) Oct 11, 2015

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

4. Adempas patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(9 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 08, 2020
New Chemical Entity Exclusivity(NCE) Oct 08, 2018
Orphan Drug Exclusivity(ODE-53) Oct 08, 2020

Drugs and Companies using RIOCIGUAT ingredient

NCE-1 date: 08 October, 2017

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents

5. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10201663 SANOFI-AVENTIS US Assembly for a drug delivery device
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

6. Airduo Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415008 TEVA PHARM Dry powder inhaler
Oct, 2034

(10 years from now)

US9066957 TEVA PHARM Dry powder inhaler
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

7. Airduo Respiclick patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957 TEVA PHARM Dry powder inhaler
Oct, 2034

(10 years from now)

US9415008 TEVA PHARM Dry powder inhaler
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

8. Alkindi Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280 ETON Composition comprising hydrocortisone
May, 2034

(9 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

ALKINDI SPRINKLE family patents

Family Patents

9. Alunbrig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
Orphan Drug Exclusivity(ODE) Apr 28, 2024
New Indication(I-847) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

Family Patents

10. Arikayce Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234 INSMED INC Systems for treating pulmonary infections
Jan, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

11. Aubagio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(9 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024
New Chemical Entity Exclusivity(NCE) Sep 12, 2017

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or adm...

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

12. Austedo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11666566

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

13. Austedo Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550780

(Pediatric)

TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

Family Patents

14. Auvelity patents expiration

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147808 AXSOME Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(10 years from now)

US11510918 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11382874 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11364233 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9457025 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US10058518 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9278095 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9867819 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9168234 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9861595 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9700553 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11357744 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11344544 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9486450 AXSOME Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(10 years from now)

US9474731 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9375429 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(10 years from now)

US9421176 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9408815 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9763932 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11311534 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9205083 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(10 years from now)

US9707191 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10898453 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11433067 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9700528 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9370513 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9457023 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9238032 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US11096937 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11298352 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10966941 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11298351 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11497721 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11090300 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10894047 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10064857 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11291665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11291638 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10786469 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11253492 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10881657 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874663 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10799497 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(10 years from now)

US11058648 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11273133 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10864209 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10806710 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10881624 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10786496 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11020389 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11185515 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10945973 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11285146 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11285118 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10596167 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US11439636 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9314462 AXSOME Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US9198905 AXSOME Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11426401 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11426370 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11419867 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11596627 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10772850 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11273134 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11253491 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11234946 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10548857 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11229640 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(10 years from now)

US11617747 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11617728 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10933034 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10251879 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11779579 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11534414 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11541021 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11541048 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11478468 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10092561 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(10 years from now)

US10894046 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11191739 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10874664 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10080727 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11197839 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11517543 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11123343 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10966974 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10512643 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10463634 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10105361 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11207281 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11141416 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11141388 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US9968568 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10105327 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US10092560 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

US11129826 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11213521 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11524008 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11524007 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US11517542 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

US10780066 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to increase dextromethorphan plasma levels

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

15. Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US11827642 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-864) Jun 16, 2024
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
New Indication(I-912) May 22, 2026

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents

16. Barhemsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention and treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BARHEMSYS family patents

Family Patents

17. Bosulif patents expiration

BOSULIF's oppositions filed in EPO
BOSULIF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(9 years from now)

US11103497

(Pediatric)

PF PRISM CV Treatment of imatinib resistant leukemia
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030
New Indication(I-923) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Chemical Entity Exclusivity(NCE) Sep 04, 2017

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...

Dosage: CAPSULE;ORAL; TABLET;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

18. Brukinsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-871) Aug 31, 2024
New Indication(I-936) Mar 07, 2027
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
New Indication(I-874) Sep 14, 2024
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

Family Patents

19. Camzyos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-398) Apr 28, 2029
New Chemical Entity Exclusivity(NCE) Apr 28, 2027
M(M-297) Jun 15, 2026

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 28 April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

Family Patents

20. Caplyta patents expiration

CAPLYTA's oppositions filed in EPO
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(10 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(10 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2024
New Indication(I-882) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

21. Cibinqo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 14, 2027
New Patient Population(NPP) Feb 09, 2026

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 14 January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

CIBINQO family patents

Family Patents

22. Clenpiq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(10 years from now)

US11191753 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(10 years from now)

US9827231 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 15, 2021

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

How can I launch a generic of CLENPIQ before it's drug patent expiration?
More Information on Dosage

CLENPIQ family patents

Family Patents

23. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events
Jul, 2034

(10 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(10 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

24. Cosela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11717523 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A m...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

Family Patents

25. Cotellic patents expiration

COTELLIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354 GENENTECH INC Combination therapies
Jun, 2034

(10 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

26. Dexycu Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(9 years from now)

US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(9 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

DEXYCU KIT family patents

Family Patents

27. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(10 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-367) Jan 24, 2027
Pediatric Exclusivity(PED) Jul 24, 2023
New Product(NP) Jan 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

28. Dilaudid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage

DILAUDID family patents

Family Patents

29. Dilaudid-hp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID-HP before it's drug patent expiration?
More Information on Dosage

DILAUDID-HP family patents

Family Patents

30. Doryx Mpc patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(10 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(10 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Apr 11, 2016
New Dosing Schedule(D-136) Apr 11, 2016

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 19 December, 2014

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX MPC before it's drug patent expiration?
More Information on Dosage

DORYX MPC family patents

Family Patents

31. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492316 ABBVIE Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

US9980974 ABBVIE Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

32. Epclusa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

US11707479 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

US9757406

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

US11707479

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

US10086011

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
M(M-264) Jul 14, 2023
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
M(M-277) Apr 27, 2025
Pediatric Exclusivity(PED) Dec 10, 2028
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Strength(NS) Mar 19, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 19 March, 2020

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

33. Epinephrine patents expiration

EPINEPHRINE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004700 BPI LABS More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(10 years from now)

US10039728 BPI LABS More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(10 years from now)

US9283197 BPI LABS More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(10 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 04 March, 2024

Treatment: Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least o...

Dosage: SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPINEPHRINE before it's drug patent expiration?
More Information on Dosage

EPINEPHRINE family patents

Family Patents

34. Evomela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872 ACROTECH BIOPHARMA Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 10, 2023
Orphan Drug Exclusivity(ODE-110) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

35. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(10 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

36. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(10 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

37. Exblifep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11124526 ALLECRA THERAPS Crystalline beta-lactamase inhibitor
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 22, 2029
Generating Antibiotic Incentives Now(GAIN) Feb 22, 2034

Drugs and Companies using CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM ingredient

NCE-1 date: 22 February, 2033

Market Authorisation Date: 22 February, 2024

Treatment: Use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

EXBLIFEP family patents

Family Patents

38. Exondys 51 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 19, 2023
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in ...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

Family Patents

39. Fabhalta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9682968 NOVARTIS Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2028
Orphan Drug Exclusivity(ODE-456) Dec 05, 2030

Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient

NCE-1 date: 06 December, 2027

Market Authorisation Date: 05 December, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

FABHALTA family patents

Family Patents

40. Firdapse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-223) Nov 28, 2025
New Patient Population(NPP) Sep 29, 2025
New Chemical Entity Exclusivity(NCE) Nov 28, 2023

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents

41. Fulvestrant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(9 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

FULVESTRANT family patents

Family Patents

42. Furoscix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272064 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

US11433044 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

US9884039 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FUROSCIX family patents

Family Patents

43. Ganzyk-rtu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530 EXELA PHARMA Ganciclovir compositions and related methods
Sep, 2034

(10 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Market Authorisation Date: 17 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

GANZYK-RTU family patents

Family Patents

44. Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US11559559 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating septic shock with angiotensin ii; Increasing blood pressure in a patient having distributive shock; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock ...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

45. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(10 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

46. Glyxambi patents expiration

GLYXAMBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

47. Gocovri patents expiration

Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646456 ADAMAS OPERATIONS Methods of administering amantadine
Jun, 2034

(10 years from now)

US11903908 ADAMAS OPERATIONS Methods of administering amantadine
Dec, 2034

(10 years from now)

US10154971 ADAMAS OPERATIONS Methods of administering amantadine
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-153) Aug 24, 2024
Orphan Drug Exclusivity(ODE) Aug 24, 2024
New Indication(I-769) Aug 24, 2020
New Product(NP) Aug 24, 2020

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant d...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage

GOCOVRI family patents

Family Patents

48. Harvoni patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
ODE*(ODE*) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE) Apr 07, 2024
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Patient Population(NPP) Apr 07, 2020
New Indication(I-718) Nov 12, 2018
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-177) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

49. Hepzato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314561 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Feb, 2034

(9 years from now)

US9707331 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 14, 2026
Orphan Drug Exclusivity(ODE-438) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: NA

Dosage: POWDER;INTRA-ARTERIAL

More Information on Dosage

HEPZATO family patents

Family Patents

50. Hetlioz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(9 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-330) Dec 01, 2027
Orphan Drug Exclusivity(ODE) Jan 31, 2021
New Indication(I-850) Dec 01, 2023
New Chemical Entity Exclusivity(NCE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-59) Jan 31, 2021

Drugs and Companies using TASIMELTEON ingredient

NCE-1 date: 31 January, 2018

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tas...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

51. Hetlioz Lq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(9 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-329) Dec 01, 2027
New Product(NP) Dec 01, 2023

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding th...

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

52. Ibrance patents expiration

IBRANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Chemical Entity Exclusivity(NCE) Feb 03, 2020

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 03 February, 2019

Market Authorisation Date: 03 February, 2015

Treatment: NA

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

53. Idhifa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10093654 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Aug, 2034

(10 years from now)

US9738625 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Aug, 2034

(10 years from now)

US9732062 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-151) Aug 01, 2024
Orphan Drug Exclusivity(ODE) Aug 01, 2024
New Chemical Entity Exclusivity(NCE) Aug 01, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: 01 August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

IDHIFA family patents

Family Patents

54. Imbruvica patents expiration

IMBRUVICA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9540382

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Feb, 2034

(9 years from now)

US9296753

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Apr, 2034

(9 years from now)

US9795604 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10695350 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10463668 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-152) Aug 02, 2024
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029
New Patient Population(NPP) Aug 24, 2025
ODE*(ODE*) Aug 02, 2024
Pediatric Exclusivity(PED) Feb 24, 2026
M(M-236) Jan 25, 2022
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Dosing Schedule(D-176) Aug 24, 2021
New Indication(I-736) May 06, 2019
New Dosing Schedule(D-165) May 06, 2019
New Indication(I-737) May 06, 2019
New Indication(I-753) Aug 02, 2020
New Indication(I-741) Jan 18, 2020
New Indication(I-680) Feb 12, 2017
New Indication(I-702) Jan 29, 2018
New Indication(I-689) Jul 28, 2017
Orphan Drug Exclusivity(ODE) Aug 02, 2024
New Indication(I-729) Mar 04, 2019
Orphan Drug Exclusivity(ODE-86) Jan 29, 2022
Orphan Drug Exclusivity(ODE-60) Feb 12, 2021
Orphan Drug Exclusivity(ODE-72) Jul 28, 2021
Orphan Drug Exclusivity(ODE-55) Nov 13, 2020
Orphan Drug Exclusivity(ODE-128) Jan 18, 2024
Orphan Drug Exclusivity(ODE-109) Mar 04, 2023
Orphan Drug Exclusivity(ODE-117) May 06, 2023

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 20 December, 2017

Treatment: Treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic ther...

Dosage: CAPSULE;ORAL; TABLET;ORAL; SUSPENSION;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

55. Imcivree patents expiration

IMCIVREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-336) Nov 25, 2027
New Chemical Entity Exclusivity(NCE) Nov 25, 2025
Orphan Drug Exclusivity(ODE-402) Jun 16, 2029
New Indication(I-892) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: 25 November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

IMCIVREE family patents

Family Patents

56. Imvexxy patents expiration

IMVEXXY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266661 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2021

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage

IMVEXXY family patents

Family Patents

57. Inomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Feb, 2034

(9 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-167) Oct 09, 2018
M(M-132) Dec 21, 2013
Pediatric Exclusivity(PED) Jun 21, 2014

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage

INOMAX family patents

Family Patents

58. Izervay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273171 ASTELLAS Methods for treating or preventing ophthalmological conditions
Jul, 2034

(10 years from now)

US11491176 ASTELLAS Methods for treating or preventing ophthalmological conditions
Jul, 2034

(10 years from now)

Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient

Market Authorisation Date: 04 August, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye

Dosage: SOLUTION;INTRAVITREAL

More Information on Dosage

IZERVAY family patents

Family Patents

59. Jadenu patents expiration

JADENU's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
Orphan Drug Exclusivity(ODE) Jan 23, 2020
M(M-239) Dec 12, 2021
Orphan Drug Exclusivity(ODE-39) Jan 23, 2020
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents

60. Jardiance patents expiration

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11666590 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 20, 2026
New Indication(I-869) Aug 18, 2024
New Indication(I-922) Sep 21, 2026
M(M-82) Feb 24, 2025
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-159) Jun 26, 2018
New Indication(I-739) Dec 02, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-160) Jun 26, 2018
M(M-161) Jun 26, 2018
M(M-174) Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

61. Jublia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864274 BAUSCH Stabilized efinaconazole formulations
Oct, 2034

(10 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(10 years from now)

US10828293 BAUSCH Anti-infective methods, compositions, and devices
Oct, 2034

(10 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(10 years from now)

US11654139 BAUSCH Anti-infective methods, compositions, and devices
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 27, 2023
New Chemical Entity Exclusivity(NCE) Jun 06, 2019

Drugs and Companies using EFINACONAZOLE ingredient

NCE-1 date: 06 June, 2018

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toe...

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage

JUBLIA family patents

Family Patents

62. Jylamvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771701 SHORLA Methotrexate formulation
Oct, 2034

(10 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate

Dosage: SOLUTION;ORAL

More Information on Dosage

JYLAMVO family patents

Family Patents

63. Kloxxado patents expiration

Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135155 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US11628139 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US11617713 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US10722510 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

US10973814 HIKMA Liquid naloxone spray
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2024

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

How can I launch a generic of KLOXXADO before it's drug patent expiration?
More Information on Dosage

KLOXXADO family patents

Family Patents

64. Leqvio patents expiration

Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

65. Liletta patents expiration

LILETTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028858 MEDICINES360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-917) Jun 29, 2026
New Product(NP) Feb 26, 2018

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

LILETTA family patents

Family Patents

66. Litfulo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9617258 PFIZER Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2028

Drugs and Companies using RITLECITINIB TOSYLATE ingredient

NCE-1 date: 24 June, 2027

Market Authorisation Date: 23 June, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

LITFULO family patents

Family Patents

67. Lodoco patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130585 AGEPHA PHARMA FZ Methods of treating and/or preventing cardiovascular disease
Dec, 2034

(10 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 16 June, 2023

Treatment: A method of treating cardiovascular disease

Dosage: TABLET;ORAL

More Information on Dosage

LODOCO family patents

Family Patents

68. Lonsurf patents expiration

LONSURF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943537 TAIHO ONCOLOGY Antitumor agent and antitumor effect enhancer
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026
New Indication(I-794) Feb 22, 2022
New Chemical Entity Exclusivity(NCE) Sep 22, 2020

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of metastatic colorectal cancer with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and i...

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

69. Loreev Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393 ALMATICA Sustained release formulations of lorazepam
Jan, 2034

(9 years from now)

Drugs and Companies using LORAZEPAM ingredient

Market Authorisation Date: 27 August, 2021

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

LOREEV XR family patents

Family Patents

70. Luzu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2018
New Patient Population(NPP) Feb 20, 2021

Drugs and Companies using LULICONAZOLE ingredient

NCE-1 date: 14 November, 2017

Market Authorisation Date: 14 November, 2013

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

LUZU family patents

Family Patents

71. Makena (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789257 COVIS Needle assisted injection device having reduced trigger force
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 03, 2018
Orphan Drug Exclusivity(ODE-7) Feb 03, 2018

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 14 February, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA (AUTOINJECTOR) before it's drug patent expiration?
More Information on Dosage

MAKENA (AUTOINJECTOR) family patents

Family Patents

72. Mavyret patents expiration

MAVYRET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286029 ABBVIE Method for treating HCV
Mar, 2034

(9 years from now)

US11484534 ABBVIE Methods for treating HCV
Mar, 2034

(9 years from now)

US11484534

(Pediatric)

ABBVIE Methods for treating HCV
Sep, 2034

(10 years from now)

US10286029

(Pediatric)

ABBVIE Method for treating HCV
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-232) Apr 30, 2026
Orphan Drug Exclusivity(ODE-233) Apr 30, 2026
Orphan Drug Exclusivity(ODE-372) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028
M(M-259) Apr 10, 2023
M(M-230) Aug 06, 2021
New Patient Population(NPP) Apr 30, 2022
New Dosing Schedule(D-175) Sep 26, 2022
New Chemical Entity Exclusivity(NCE) Aug 03, 2022

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents

73. Mekinist patents expiration

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
New Indication(I-908) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Dec 22, 2025
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-678) Jan 08, 2017
M(M-246) Oct 06, 2022
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
Orphan Drug Exclusivity(ODE) May 29, 2020
New Chemical Entity Exclusivity(NCE) May 29, 2018

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

MEKINIST family patents

Family Patents

74. Morphine Sulfate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(9 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

US9192608 FRESENIUS KABI USA